Amgen settles US cases for $762m

Amgen Inc. has agreed to pay $762 million to resolve federal litigation accusing the drug maker of marketing the anemia treatment Aranesp for unapproved uses.

The company pleaded guilty Tuesday to illegally introducing a misbranded drug into interstate commerce and will pay a $136 million fine and a $14 million forfeiture, according to the US Attorney’s Office for the Eastern District of New York.


It also agreed to a $612 million civil settlement according to a law firm connected to the case.

But the US attorney’s office declined to comment on that because the civil settlement won’t be unsealed until a Wednesday court hearing.

Amgen said in an e-mail that if the court accepts the plea and sentence, it will immediately resolve civil and criminal matters.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of